Polymerase chain reaction

Polymerase chain reaction is the decisive molecular instrument in the book’s account of hepatitis C virus. Serological evidence can show that a person has encountered the virus, but polymerase chain reaction detects whether HCV RNA remains in the blood. That distinction governs diagnosis, treatment, transplant assessment, treatment continuation or withdrawal, and the investigation of transmission within dialysis units.

Diagnostic Function

Polymerase chain reaction establishes the boundary between past exposure and active disease. Third-generation enzyme-linked immunosorbent assay detects anti-HCV antibodies, but antibody positivity alone cannot distinguish resolved infection from chronic infection. Chronic infection is defined by the combination of anti-HCV positivity and detectable HCV RNA, with active chronic infection requiring persistence for more than six months. The molecular threshold described for these assays is approximately 15 IU/ml, making the test sensitive enough to identify low-level circulating virus.

This distinction is clinically consequential rather than merely technical. A patient may retain antibodies after recovery while no longer carrying detectable virus; polymerase chain reaction therefore prevents serological memory from being mistaken for ongoing infection. Conversely, a positive RNA result identifies viremia and requires assessment of both hepatic injury and extrahepatic disease, including cryoglobulinemia-associated vasculitis and renal involvement.

Screening and Clinical Staging

Polymerase chain reaction also determines how hepatitis C is screened in people being considered for kidney transplantation. In regions with a low prevalence of infection, the recommended sequence begins with an enzyme immunoassay, followed by nucleic acid testing for patients whose antibody result is positive. In high-prevalence settings, nucleic acid testing is recommended as the initial screening method because a negative antibody assay cannot reliably exclude infection. The test thus serves both as confirmation and, in particular epidemiological settings, as the primary gatekeeper for identifying viremia.

A positive RNA result does not by itself describe the extent of liver damage. Once active infection has been established, the liver must be evaluated by biopsy or noninvasive methods such as FibroScan and biochemical fibrosis scores, while extrahepatic effects are assessed separately. This separation is important because up to one quarter of candidates with active infection have advanced fibrosis despite well-compensated liver disease and no obvious clinical suspicion. Polymerase chain reaction identifies the virus; it does not replace the structural and pathological assessment of the organs affected by it.

Treatment Monitoring

During antiviral therapy, polymerase chain reaction becomes a clock as well as a detector. Patients who ultimately achieve sustained virologic response typically show a rapid first decline in HCV RNA, followed by a slower phase associated with clearance of infected cells. Early virologic response is classically defined as at least a 99 percent decrease in HCV RNA at week 12. A complete early virologic response means that RNA is undetectable at that point, whereas a partial response retains a positive molecular result despite the 99 percent fall.

The timing of the result changes its predictive meaning. Complete early virologic response has a positive predictive value of 72 percent for sustained virologic response; a partial response has a lower value of 21 percent, compared with 84 percent when HCV RNA is undetectable at week 12. A negative qualitative polymerase chain reaction at week 4 constitutes rapid viral response and carries a sustained-response predictive value of roughly 90 percent in patients infected only with HCV and 82 percent in coinfected patients. The extended rapid response designation requires undetectable HCV RNA at both weeks 4 and 12.

These serial measurements determine whether treatment is shortened, prolonged, or stopped. In genotype 1 infection, therapy is discontinued when the viral load has not fallen by 99 percent at week 12, and it is stopped in all cases when the week-24 molecular test remains positive because the chance of sustained response is then about 1 percent. Patients with partial early response and those with a negative week-24 result may receive 72 weeks of treatment. In genotype 3 infection, treatment is extended to 48 weeks when complete early response is not achieved, while genotype 2 patients are described as consistently achieving complete early response.

Transmission Investigation

In hemodialysis units, polymerase chain reaction extends beyond individual diagnosis into molecular epidemiology. Sequencing variable portions of the HCV genome allows investigators to fingerprint viral isolates or quasi-species. Closely related isolates from patients in the same unit can form phylogenetic clusters, and those clusters, combined with dialysis-unit epidemiology, provide evidence that infections arose from a common source or through nosocomial transmission.

The method does not automatically identify the precise breach or route. A systematic review of 20 molecular-virology studies found that none conclusively established the specific transmission pathway, although every study implicated failures in infection-control procedures. In 18 of the 20 studies, some or all newly infected patients had not shared a dialysis machine with the presumed source patient. This pattern made the internal fluid pathway of the dialysis machine appear, at most, a minor contributor, while shared care environments and lapses in hygiene became the more plausible explanation.

When a dialysis patient seroconverts, polymerase chain reaction and molecular comparison can help test whether infection was acquired inside or outside the unit. Investigators consider intravenous drug use, travel, dialysis in a high-risk country, transfusion abroad, simultaneous treatment in a ward containing an HCV-positive patient, and less likely exposure through the same monitor. If molecular evidence supports transmission within the unit, the response is to reinforce basic hygienic precautions and actively search for additional cases, preferably with nucleic acid testing.

Transplant and Pathological Relevance

The molecular result remains important after transplantation, where HCV infection is associated with immune-complex glomerulonephritis, proteinuria, and poor renal-allograft outcomes. In HCV-infected renal allograft recipients with de novo membranoproliferative glomerulonephritis, HCV RNA is usually much higher in the cryocrit than in serum, supporting a pathogenic role for the virus in cryoglobulinemia even when serum cryocrit levels are very low. Polymerase chain reaction therefore contributes to the connection between circulating virus, immune complexes, and renal injury, although it cannot by itself establish the full pathological mechanism.

The test also marks an unresolved boundary in the use of kidneys from HCV-positive donors. Recent recommendations have suggested nucleic acid testing of donors, but information about donor HCV RNA status was lacking in the cited experience. The absence of those data did not appear likely to alter the proposed allocation strategy for HCV-positive kidneys, yet it limited the ability to assess active transmission risk. Similarly, missing donor and recipient genotype information prevented evaluation of superinfection and its clinical implications. Polymerase chain reaction thus supplies the factual basis for modern HCV classification, while the book repeatedly shows that its interpretation depends on timing, clinical context, genotype, pathology, and the consequences of acting on the result.